| Modality | Compounds | Indication | MoA | Development Stage | 비고 | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Poc | Hit | H-to-L | Lead Opt. | Pre-clinical | Clinical | |||||
| Small molecule |
OGS-101* | Parkinson’s disease |
Mitophagy Inducer |
Lead Optimization
|
||||||
| OGS-101-1 | Myopathy |
PoC&Hit 도출
|
||||||||
| OGS-101-2 | Hearing loss |
PoC
|
||||||||
| OGS-102 | undisclosed |
Hit 도출
|
||||||||
| OGS-801 | 항암제(EGFR TKI) 내성암 |
Autophagy Inhibitor |
Hit 도출
|
|||||||
| OGS-701 | 희귀질환 | Ciliogenesis Inducer |
Hit 도출
|
|||||||
*OGS-101-1&2, etc : 공동개발을 통해 적응증 확장(퇴행성뇌질환; AD, ALS / 난청 / 녹내장 / Myopathy(근질환) 등)